![]() ![]() On the other hand, if CUNY finds nothing concerning in any investigation and announces this, that would serve as a major validation of Dr. H-YW refers to Hoau-Yan Wang, ZP to Zhe Pei (also at CUNY) and Kuo-Chieh Lee (also at CUNY). Source: Statement from the Author Contributions section of a preprint, first available February 24, 2021. Wang with analysis of biomarker samples from a phase 2 trial of simufilam.īiomarker analyses were conducted blind to treatment and time point by H-YW, ZP and K-CL. A statement from the Author Contributions section of a preprint, titled "Effects of simufilam on cerebrospinal fluid biomarkers in Alzheimer’s disease: A randomized clinical trial," confirms the involvement of Dr. Wang isn't just behind some of the basic and preclinical research concerning simufilam and Filamin A in Alzheimer's disease. Obviously, we are not talking about edits to images which don't impact the results, rather editing that would change the stated results and hence conclusions drawn from those results. If CUNY confirms that the original films and images don't match what was published, then SAVA stock could fall. Remi Barbier, CEO of SAVA, September 3 public statement, emphasis mine. I have also asked CUNY that its conclusionary findings be made available to the public. For this reason, I have respectfully requested that CUNY inquire thoroughly but expeditiously into the allegations targeting Prof. Those were generated by our science collaborator at CUNY, who is Prof. For this reason, we don’t have the original films or images for the Western blots in question. As a reminder, Cassava Sciences does not have its own laboratory facilities. One way to settle the discourse around Western blots might be to go back to the original films and images. Wang's work by The City University of New York (CUNY). Hoau-Yan Wang, Remi Barbier, noted that he had requested a review of Dr. Potential for confirmation of image editingįollowing allegations by the Citizen Petition concerning the work of Dr. I don't actually view the 12-month data as doing much at this point based on the price action on the day of release, indeed the release interrupted an uptrend in SAVA's stock that had started a week earlier. In summary, SAVA appears to have done its best to put out the fire, for now, in its stock, with action from the CEO and Dr. ![]() Indeed there was some criticism of the reporting of those results, which provided no baseline data in the press release, something that might have helped interpret the result. SAVA in fact closed down for the day on September 22, despite an initial rally with the release of results. Her continued answers throughout early and mid-September may have reassured some investors, her science background being of use in providing compelling answers to technical questions.Īlso, on September 22, SAVA announced 12-month data from an open-label trial of simufilam, which saw the first 50 Alzheimer's disease patients to complete 12 months of treatment improve 3.2 points on the ADAS-Cog11. Burns' comments seem to have done a pretty good job regarding questions on experiments conducted and reported in that particular pre-print. Lindsay Burns, Senior Vice President, Neuroscience at SAVA, replied to questions on a preprint (something made available online prior to official publication of a paper in a journal) titled "Effects of simufilam on cerebrospinal fluid biomarkers in Alzheimer’s disease: A randomized clinical trial." Some of Dr. These steps included a statement (September 3) and presentation at a conference (September 9) from CEO Remi Barbier. Firstly, Why The Reversal?įollowing an initial response on August 27 to allegations raised in a Citizen Petition concerning the science behind simufilam, SAVA took several additional steps to respond to the allegations. Data by YChartsįigure 1: SAVA trading, past six months. ![]() This article looks at why SAVA might have found a bottom and began climbing again and a few catalysts that could impact SAVA stock. Clearly, concern over simufilam isn't gone completely, but the question of if SAVA will recover further remains. While SAVA appeared to find a clear bottom just below $40 in mid-September, and is now well off those lows, the name is still well off recent highs. During the past month, Cassava Sciences ( NASDAQ: SAVA) has done its best to hit back at allegations regarding the science behind simufilam, the company's Alzheimer's disease drug.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |